Iroquois Capital Group

RS Metrics specializes in providing asset-level environmental, climate, and physical risk metrics tailored for various stakeholders. In 2023, the company partnered with Google Cloud to enhance accessibility to its extensive suite of over 100 metrics through software as a service (SaaS), data as a service (DaaS), and dashboards. Their flagship products, ESGSignals® and AssetTracker, leverage a decade of model-driven architecture and advanced technologies in artificial intelligence and data science to deliver timely, independent, and verifiable environmental insights. The collaboration with Google Cloud enables the creation of efficient climate risk analytics frameworks for lending and investment portfolios, utilizing granular geospatial datasets. ESGSignals® features a comprehensive array of analysis-ready data (ARD) metrics, which are real-time, auditable, and scalable, facilitating objective valuation and informed decision-making in sustainable finance and enterprise risk management.

Iroquois Security Monitoring provides security alarm products and services. ISM specializes in managing residential security alarm systems and provides services such as fire alarm, theft alarm, and smoke alarm installations.

Community Care Solutions partners with rural hospitals to implement pain management programs. Community Care Solutions brings pain management and interventional pain management services to community hospitals.

Covenant Physician Partners is a privately-held company that owns and operates ambulatory surgery centers, focusing on providing high-quality surgical care. It specializes in minimally invasive and robotic technologies for procedures related to colorectal cancer screening, polyp removal, and digestive tract surgery. In addition to surgical services, Covenant manages anatomic pathology laboratories and physician practices, offering essential back-office functions such as human resources, billing, contract negotiations, and accounting. This comprehensive support allows healthcare professionals to concentrate on patient care while ensuring efficient operational management within their practices.

ACS Partners specializes in construction services, focusing on both commercial and residential markets. The company offers a range of services, including renovations for multi-family complexes, student housing, and single-family homes. With a commitment to quality, ACS Partners addresses the diverse needs of developers in the construction sector.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapeutic products for cancer treatment. The company's lead product candidate, tucatinib, is an oral, HER2-selective small molecule tyrosine kinase inhibitor currently undergoing two Phase Ib clinical trials for metastatic breast cancer in combination therapies. In addition to tucatinib, Cascadian Therapeutics is advancing its preclinical pipeline, which includes CASC-578, a Chk1 cell cycle inhibitor, and CASC-674, an antibody targeting immuno-oncology. The company has established collaborative agreements with Array BioPharma for tucatinib development, Sentinel Oncology for novel Chk1 inhibitors, and Adimab for discovering new antibodies targeting immunotherapy in oncology. Founded in 1985 and formerly known as Oncothyreon Inc., Cascadian Therapeutics continues to focus on providing targeted therapies that aim to improve cancer treatment outcomes.

Raptor Pharmaceuticals Corp. is a development stage biotechnology company based in Novato, California, focused on discovering and developing innovative drug candidates for various serious conditions, including brain disorders, neurodegenerative diseases, genetic disorders, and cancers. The company is advancing several clinical-stage products, including DR Cysteamine, which is undergoing Phase IIb trials for nephropathic cystinosis and Phase IIa trials for non-alcoholic steatohepatitis, as well as Convivia for ALDH2 deficiency and additional candidates targeting Huntington's disease and migraine. Raptor is also engaged in preclinical development of therapies such as HepTide for hepatocellular carcinoma, WntTide for breast cancer, and NeuroTrans for neurodegenerative diseases. The company collaborates with academic institutions, including the University of California, San Diego, to enhance its research and clinical studies. Founded in 2005, Raptor Pharmaceuticals is dedicated to developing bio-pharmaceutical therapies aimed at treating debilitating and life-threatening diseases.

Soligenix, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases and public health solutions. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma that has completed Phase 3 clinical trials, and SGX942, aimed at treating oral mucositis in head and neck cancer, currently in Phase 3 trials. Additionally, it is developing an oral formulation of beclomethasone dipropionate for severe gastrointestinal disorders in early clinical trials. The Public Health Solutions segment focuses on biodefense, including the development of RiVax, a vaccine candidate against ricin toxin, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections that is in pre-clinical development. The company also works on technologies like ThermoVax, aimed at stabilizing vaccines. Soligenix was founded in 1987 and is based in Princeton, New Jersey.

TapImmune engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada.

Sevion Therapeutics is a biopharmaceutical company focused on discovering, developing, and acquiring innovative therapies for cancer and immunological diseases. The company advances a pipeline of proprietary and partnered product candidates utilizing its unique antibody technology platforms. This pipeline aims to create biologic therapies targeting previously inaccessible areas, including multispanning membrane proteins and ion channels involved in various diseases. Additionally, Sevion has developed a pioneering protein nanocage system designed for the targeted delivery of nucleic acids and other therapeutic payloads to specific cells. Through its research and development efforts, Sevion is dedicated to addressing critical therapeutic needs in the treatment of cancer and inflammatory diseases.

Biomoda, Inc. is a development stage company based in Albuquerque, New Mexico, focused on in-vitro diagnostics, particularly in the detection of cancer. The company is advancing its key product, CyPath, an assay designed to identify early-stage lung cancer through a non-invasive method. This diagnostic test utilizes a patented porphyrin application that selectively binds to cancerous cells in deep-lung sputum samples. In addition to lung cancer, Biomoda is exploring diagnostic protocols for other types of cancer, including breast and prostate cancer. The company collaborates with the New Mexico Institute of Mining and Technology for clinical studies aimed at early lung cancer detection among veterans. Furthermore, Biomoda has partnered with Medical Acoustics, LLC for the use of its Lung Flute device in sample collection, and has secured consulting agreements to navigate the FDA approval process. Founded in 1990, Biomoda is committed to developing innovative solutions for cancer detection.

SinoHub, Inc. is an electronics company based in Shenzhen, China, operating in two main segments: Integrated Contract Manufacturing (ICM) and Electronic Component Sales and Services (ECSS). The ICM segment specializes in custom, private label mobile phones and tablets, primarily targeting customers in developing countries. Meanwhile, the ECSS segment focuses on the sale of electronic components to manufacturers and design houses, as well as providing comprehensive supply chain management services, which encompass warehousing, logistics, delivery, and import/export operations. Additionally, SinoHub offers a proprietary web-based software platform that facilitates the management of electronic component procurement and logistics, providing functionalities such as order entry, inventory management, and shipment tracking. Founded in 2000, SinoHub serves a diverse clientele, including original equipment manufacturers (OEMs) and electronic manufacturing services (EMS) companies.

VeriTeQ is a technology company based in Delray Beach, Florida, specializing in identification solutions for animals and emergencies. Founded in 1993, the company offers a range of products including FDA-approved implantable microchips for pet identification, visual and radio frequency identification (RFID) ear tags for livestock tracking, and GPS search and rescue beacons designed for use on aircraft, ships, and by outdoor enthusiasts. Additionally, VeriTeQ develops RFID technologies for identifying implantable medical devices utilized in radiation therapy and is creating a data analytics platform aimed at enhancing evidence-based healthcare through the collection of treatment regimen data.

CEL-SCI Corporation is a biotechnology company based in Vienna, Virginia, that focuses on the research and development of immunotherapy products for cancer and infectious diseases. Its leading investigational therapy, Multikine, is currently undergoing phase III clinical trials for treating head and neck cancer. Additionally, CEL-SCI has developed a proprietary platform known as the Ligand Epitope Antigen Presentation System (LEAPS), which aims to enhance the human immune response against various health issues, including bacterial, viral, and parasitic infections, as well as autoimmune diseases and cancer. The company is also exploring other product candidates, such as LEAPS-H1N1-DC for influenza, CEL-2000 and CEL-4000 for rheumatoid arthritis, and LEAPS COV-19 for COVID-19. CEL-SCI collaborates with the University of Georgia’s Center for Vaccines and Immunology to advance its COVID-19 immunotherapy efforts. Founded in 1983, CEL-SCI continues to innovate in the biopharmaceutical sector.

Agenus Inc. is a clinical-stage immuno-oncology company focused on the discovery, development, and commercialization of innovative immunotherapies and vaccines for cancer and infectious diseases. Based in Lexington, Massachusetts, the company aims to activate the immune system to recognize and combat cancer cells through a diverse portfolio that includes checkpoint antibodies, tumor microenvironment modifiers, and vaccine adjuvants. Agenus utilizes its proprietary Retrocyte Display platform for antibody discovery and develops a range of therapeutic candidates, including monoclonal antibodies and vaccines targeting various tumor-specific neo-epitopes. The company has several products in clinical trials, including CTLA-4 and PD-1 antagonists, and collaborates with notable partners such as Incyte Corporation and Merck Sharpe & Dohme to advance its immuno-oncology therapies. Founded in 1994, Agenus continues to build its capabilities in research, development, and manufacturing within the field of immunotherapy.

ACE*COMM Corporation was a provider of operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Their solutions were designed for wired, wireless, voice, data, multimedia, and Internet communication networks. Operating in various regions including the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific, ACE*COMM established strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. Founded in 1983 and headquartered in Gaithersburg, Maryland, the company focused on delivering essential tools for efficient network operations and management in the telecommunications industry.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Migo Software, Inc. engages in the development, acquisition, and marketing of software and infrastructure technologies designed for the storage and accession of personalized mobile information. Its flagship product, Migo, allows users to synchronize their personalized computing environments, including email, digital media, and other data; and application settings to portable storage devices, such as flash/hard disk drives, smart phones, and MP3 players. The company also offers XP to Vista Easy-Sync Suite that provides a safety net and applications support for users transitioning their data and computing environment to a new or upgraded computer running Microsoft’s Windows Vista Operating System; Registry Repair, which fixes computer problems, such as system lock-ups and freezes; PC BackUp, a disaster recovery tool that simplifies the computer backup process; and Recover Lost Data, an utility for retrieving files. In addition, it provides Digital Vault/Portable Vault, Digital File Shedder, DriveWasher, and Easy PC Transfer that offer a line of backup, system utility, and online security/privacy for the users. Migo Software sells its products primarily through original equipment manufacture partnerships, resellers, and through its Web site in the United States and internationally. The company was formerly known as Powerhouse Technologies Group, Inc. and changed its name to Migo Software, Inc. in 2006. Migo Software is headquartered in Redwood City, California.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

BravoSolution SpA specializes in supply management technology software and services aimed at enhancing procurement and sourcing processes. The company provides a range of solutions, including Spend Analysis to optimize savings and compliance, eSourcing for collaborative sourcing efforts, and supplier performance management tools. Its Contract Management service streamlines contract processes to ensure users realize savings from their negotiations. Notable products include BravoAlign, a cloud-based procurement alignment solution, and BravoAdvantage, a comprehensive platform that supports procurement initiatives from demand to contract. Additionally, BravoAdvantage Analytics offers data visualization tools, enabling procurement professionals to create intuitive reports and dashboards. BravoSolution also delivers collaboration services and government solutions related to spend visibility and electronic sourcing. Founded in 2000 and headquartered in Milan, Italy, BravoSolution operates offices in multiple countries, including the United States, Brazil, and several European nations. As of late 2017, it functions as a subsidiary of JAGGAER, Inc.

Pharmacopeia, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutics for unmet medical needs. The company's internal program portfolio includes PS433540, a dual-acting angiotensin and endothelin receptor antagonist currently in phase II clinical development for cardiovascular and renal diseases, such as hypertension and diabetic nephropathy. Additionally, PS178990, a muscle selective SARM agonist, is in phase I clinical development. Pharmacopeia also has a preclinical product, PS031291, aimed at treating multiple myeloma and inflammatory diseases like rheumatoid arthritis, as well as JAK3 inhibitors targeting T-cell and cytokine mediated dermatologic and ocular conditions, including psoriasis and dry eye. The company has formed strategic alliances with several pharmaceutical firms, enhancing its research and development capabilities. Founded in 1993 and based in Cranbury, New Jersey, Pharmacopeia was previously known as Pharmacopeia Drug Discovery, Inc. and became a subsidiary of Ligand Pharmaceuticals Inc. in 2008.